S&P 500   4,585.36 (+0.40%)
DOW   34,529.70 (+0.13%)
QQQ   395.37 (+0.39%)
AAPL   168.35 (+1.85%)
MSFT   335.93 (+1.62%)
FB   317.19 (-2.24%)
GOOGL   2,879.63 (+1.47%)
AMZN   3,496.29 (-0.31%)
TSLA   1,137.60 (-0.63%)
NVDA   323.38 (-1.03%)
BABA   125.05 (-1.94%)
NIO   39.58 (+1.15%)
CGC   10.31 (-3.73%)
AMD   153.32 (-3.19%)
GE   95.00 (+0.01%)
MU   87.25 (+3.87%)
T   22.45 (-1.66%)
F   19.98 (+4.12%)
DIS   144.60 (-0.21%)
PFE   54.41 (+1.27%)
ACB   6.22 (-3.12%)
AMC   31.31 (-7.75%)
BA   193.13 (-2.39%)
S&P 500   4,585.36 (+0.40%)
DOW   34,529.70 (+0.13%)
QQQ   395.37 (+0.39%)
AAPL   168.35 (+1.85%)
MSFT   335.93 (+1.62%)
FB   317.19 (-2.24%)
GOOGL   2,879.63 (+1.47%)
AMZN   3,496.29 (-0.31%)
TSLA   1,137.60 (-0.63%)
NVDA   323.38 (-1.03%)
BABA   125.05 (-1.94%)
NIO   39.58 (+1.15%)
CGC   10.31 (-3.73%)
AMD   153.32 (-3.19%)
GE   95.00 (+0.01%)
MU   87.25 (+3.87%)
T   22.45 (-1.66%)
F   19.98 (+4.12%)
DIS   144.60 (-0.21%)
PFE   54.41 (+1.27%)
ACB   6.22 (-3.12%)
AMC   31.31 (-7.75%)
BA   193.13 (-2.39%)
S&P 500   4,585.36 (+0.40%)
DOW   34,529.70 (+0.13%)
QQQ   395.37 (+0.39%)
AAPL   168.35 (+1.85%)
MSFT   335.93 (+1.62%)
FB   317.19 (-2.24%)
GOOGL   2,879.63 (+1.47%)
AMZN   3,496.29 (-0.31%)
TSLA   1,137.60 (-0.63%)
NVDA   323.38 (-1.03%)
BABA   125.05 (-1.94%)
NIO   39.58 (+1.15%)
CGC   10.31 (-3.73%)
AMD   153.32 (-3.19%)
GE   95.00 (+0.01%)
MU   87.25 (+3.87%)
T   22.45 (-1.66%)
F   19.98 (+4.12%)
DIS   144.60 (-0.21%)
PFE   54.41 (+1.27%)
ACB   6.22 (-3.12%)
AMC   31.31 (-7.75%)
BA   193.13 (-2.39%)
S&P 500   4,585.36 (+0.40%)
DOW   34,529.70 (+0.13%)
QQQ   395.37 (+0.39%)
AAPL   168.35 (+1.85%)
MSFT   335.93 (+1.62%)
FB   317.19 (-2.24%)
GOOGL   2,879.63 (+1.47%)
AMZN   3,496.29 (-0.31%)
TSLA   1,137.60 (-0.63%)
NVDA   323.38 (-1.03%)
BABA   125.05 (-1.94%)
NIO   39.58 (+1.15%)
CGC   10.31 (-3.73%)
AMD   153.32 (-3.19%)
GE   95.00 (+0.01%)
MU   87.25 (+3.87%)
T   22.45 (-1.66%)
F   19.98 (+4.12%)
DIS   144.60 (-0.21%)
PFE   54.41 (+1.27%)
ACB   6.22 (-3.12%)
AMC   31.31 (-7.75%)
BA   193.13 (-2.39%)
NYSE:PEN

Penumbra Stock Forecast, Price & News

$245.49
-0.16 (-0.07%)
(As of 12/1/2021 01:52 PM ET)
Add
Compare
Today's Range
$244.44
$250.25
50-Day Range
$245.65
$288.00
52-Week Range
$163.49
$320.00
Volume
4,235 shs
Average Volume
268,577 shs
Market Capitalization
$9.17 billion
P/E Ratio
269.77
Dividend Yield
N/A
Beta
0.26
30 days | 90 days | 365 days | Advanced Chart
Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.


Penumbra logo

About Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Headlines

Notable Penumbra Insider Trades $750K In Company Stock
November 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,300
Year Founded
N/A

Sales & Book Value

Annual Sales
$560.41 million
Cash Flow
$0.50 per share
Book Value
$18.33 per share

Profitability

Net Income
$-15.70 million
Pretax Margin
4.21%

Debt

Price-To-Earnings

Miscellaneous

Free Float
34,557,000
Market Cap
$9.17 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

MarketRank

Overall MarketRank

2.58 out of 5 stars

Medical Sector

85th out of 1,392 stocks

Surgical & Medical Instruments Industry

12th out of 127 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Penumbra (NYSE:PEN) Frequently Asked Questions

Is Penumbra a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Penumbra stock.
View analyst ratings for Penumbra
or view top-rated stocks.

How has Penumbra's stock been impacted by COVID-19?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PEN shares have increased by 38.8% and is now trading at $245.49.
View which stocks have been most impacted by COVID-19
.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Penumbra
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported $0.12 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.14 by $0.02. Penumbra had a net margin of 4.72% and a trailing twelve-month return on equity of 5.77%. During the same period in the prior year, the firm earned $0.06 earnings per share.
View Penumbra's earnings history
.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $735 million-$740 million, compared to the consensus revenue estimate of $727.14 million.

What price target have analysts set for PEN?

6 equities research analysts have issued 1-year price targets for Penumbra's stock. Their forecasts range from $308.00 to $350.00. On average, they anticipate Penumbra's share price to reach $334.00 in the next twelve months. This suggests a possible upside of 36.1% from the stock's current price.
View analysts' price targets for Penumbra
or view top-rated stocks among Wall Street analysts.

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Adam Elsesser, Chairman, President & Chief Executive Officer
  • Ben Sorci, Executive Vice President-Operations
  • Maggie S. Yuen, Chief Financial Officer
  • Michaella Corso, Vice President-Clinical Affairs
  • Pankaj Tiwari, Vice President-Information Technology

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra CEO Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among Penumbra's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.62%), Capital Research Global Investors (7.41%), Baillie Gifford & Co. (3.62%), William Blair Investment Management LLC (1.83%), Capital World Investors (1.36%) and Geode Capital Management LLC (1.10%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends for Penumbra
.

Which major investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Capital Research Global Investors, Capital World Investors, Franklin Resources Inc., New York State Common Retirement Fund, Renaissance Technologies LLC, Citadel Advisors LLC, and Cubist Systematic Strategies LLC. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Harpreet Grewal, James Robert Pray, Johanna Roberts, Surbhi Sarna, and Thomas Wilder.
View insider buying and selling activity for Penumbra
or view top insider-selling stocks.

Which major investors are buying Penumbra stock?

PEN stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Point72 Asset Management L.P., Balyasny Asset Management LLC, Balyasny Asset Management LLC, Natixis, Neuberger Berman Group LLC, Engine NO. 1 LLC, and Pura Vida Investments LLC.
View insider buying and selling activity for Penumbra
or or view top insider-buying stocks.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $245.49.

How much money does Penumbra make?

Penumbra has a market capitalization of $9.17 billion and generates $560.41 million in revenue each year. The company earns $-15.70 million in net income (profit) each year or $0.91 on an earnings per share basis.

How many employees does Penumbra have?

Penumbra employs 3,300 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

Where are Penumbra's headquarters?

Penumbra is headquartered at One Penumbra Place, Alameda CA, 94502.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at (510) 748-3200, via email at [email protected], or via fax at 510-748-3232.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.